Welcome to Paratek Medical Affairs
This web portal is intended as an educational resource for healthcare professionals practicing in the U.S. Information provided is for informational purposes and is not intended to promote the use of any product. Please review the relevant package insert for safety information and directions for use before prescribing medications.
Are you a health professional practicing in the United States?

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Paratek Medical Affairs Site

This website was developed by Paratek Medical Affairs professionals as a resource for healthcare professionals practicing in the United States.

The information provided on this website is for informational purposes and is not intended to promote the use of any product.

Upcoming Events

CHEST 2025
October 19-22 2025
Chicago, IL

ID Week 2025
October 19-22, 2025
Atlanta, GA






Paratek Sponsored Educational Programs

The below CME program was supported by Paratek Pharmaceuticals, Inc

CABP
Practical Considerations for the Management of Bacterial Community-Acquired Pneumonia
Objectives:
     1. Discuss the diagnostic criteria and classification of CAP
     2. Apply evidence-based approaches to treatment selection for severe bacterial CAP
      3. Review the guidelines for therapeutic management of CAP
      4. Explain how to integrate clinical evidence into treatment selection for patients with comorbidities.

Available until May 2, 2026

--------------------------------------------------------------------------------------------------------------------------------------------------------------------

The CME program was supported by an independent educational grant from Paratek Pharmaceuticals, Inc. The materials presented in the CME program was not created or influenced by Paratek and do not reflect the views of Paratek. These materials may discuss uses and dosages for therapeutic products that may not be approved by the FDA and are not intended to promote any product or indication outside of an FDA-approved use. Prescribers should consult the FDA-approved Prescribing Information for each individual product.

Please check back for updates

Contact Us

If you would like to speak to a Paratek Medical Information Professional please call 1-833-PARATEK (1-833-727-2835) or email medinfo@paratekpharma.com. Otherwise please see below.

Medical Information
If you would like to speak to a Paratek Medical Information Professional or speak with a Field Medical professional about NUZYRA®:

Call: 1-833-PARATEK (1-833-727-2835)
Email: medinfo@paratekpharma.com

With our commitment to patient safety, if you are reporting an adverse event or product complaint, please report as much relevant information as possible which may include product indication, lot number and return availability.

If you would like to speak to a Paratek Medical Information Professional or speak with a Field Medical professional about XHANCE®:

Call:  1-833-678-6673
Email:  ReportAE@optinose.com
Report a Product Complaint
To report a Product Quality Complaint for NUZYRA®:

Call: 1-833-PARATEK (1-833-727-2835)
Email: drugsafety@propharmagroup.com

To report a Product Quality Complaint for XHANCE®:
Call:  1-833-678-6673
Email:  ReportAE@optinose.com
Report an Adverse Event
To report an Adverse Event for NUZYRA®:

Call: 1-833-PARATEK (1-833-727-2835)
Email: drugsafety@propharmagroup.com

To report an Adverse Event for XHANCE®:
 Call:  1-833-678-6673
Email:  ReportAE@optinose.com

You can also contact the FDA:

Call:  1-800-FDA-1088
Email: www.fda.gov/medwatch